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Objectives The aim of this prospective, multicenter, observational study was to compare the prognostic value of Doppler
echocardiographic-derived coronary flow reserve (CFR) in diabetic and nondiabetic patients with known or sus-
pected coronary artery disease and negative dipyridamole stress echocardiography.
Background The prognostic value of CFR in diabetic patients with negative stress echocardiography remains unknown.
Methods The study group consisted of 1,130 patients (207 diabetics) with known (n  418) or suspected (n  712) coro-
nary artery disease and negative stress echocardiography by wall motion criteria. All underwent dipyridamole (up
to 0.84 mg/kg over 6 min) echocardiography with CFR evaluation of left anterior descending artery by Doppler.
A value of CFR 2.0 was considered abnormal.
Results Coronary flow reserve was abnormal in 309 (27%) patients. During a median follow-up of 16 months, 98 events
(8 deaths, 24 ST-segment elevation myocardial infarctions, and 66 non–ST-segment elevation myocardial infarc-
tions) occurred. In addition, 101 patients underwent revascularization and were censored. Multivariable prognos-
tic indicators were abnormal CFR (p  0.0001), anti-ischemic therapy at the time of testing (p  0.002), age
(p  0.02), and resting wall motion abnormality (p  0.05). The event rate was markedly higher (p  0.0001)
for both diabetic and nondiabetic patients with abnormal CFR as compared with diabetic and nondiabetic pa-
tients with normal CFR. Of note, a preserved CFR off therapy identified diabetic and nondiabetic patients with
better survival and comparable yearly event rates (2.2% vs. 2.0%, p  0.80).
Conclusions Coronary flow reserve provides independent prognostic information in diabetic and nondiabetic patients with
known or suspected coronary artery disease and negative dipyridamole stress echocardiography. In particular,
a normal CFR off therapy is associated with better and similar survival in the 2 populations. (J Am Coll Cardiol
2007;50:1354–61) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.06.027T
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tisk stratification of diabetic patients is a major objective for
he clinical cardiologist, given their increased risk for coro-
ary artery disease (CAD) (1,2). Although stress echocar-
iography provides useful prognostic information in these
atients (3–7), a negative test result is associated with less
enign outcome in the presence of diabetes (7). This calls
or more effective prognostic modalities in diabetic subjects.
rom the *Cardiology Division, Campo di Marte Hospital, Lucca, Italy; †Cardiology
ivision, Umberto I° Hospital, Mestre, Italy; ‡Cardiology Division, Cesena Hospital,
esena, Italy; §CNR, Institute of Clinical Physiology, Pisa, Italy; and the Depart-
ent of Clinical and Experimental Medicine, Federico II University Hospital,
aples, Italy.c
Manuscript received April 26, 2007; revised manuscript received June 6, 2007,
ccepted June 20, 2007.he combined evaluation of wall motion and coronary flow
eserve (CFR) in the left anterior descending artery (LAD)
uring dipyridamole stress echocardiography has been re-
ently proposed as a feasible (8) and accurate method for the
iagnosis of CAD, increasing test sensitivity with modest
oss in specificity (9–14). In a previous study, abnormal
FR was found to correlate with unfavorable outcome in
atients with known or suspected CAD and negative stress
chocardiography result by wall motion criteria (15). How-
ver, the relative prognostic importance of CFR over wall
otion analysis remains to be established in the diabetic
opulation. In fact, several studies, mainly in type 2 diabe-
es, have documented a reduced CFR even in the absence of
oronary obstructive disease and using different techniques
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entricle globally (17) as well as regionally (16), and there-
ore the CFR assessment on LAD, which would be inade-
uate for CAD detection, is an excellent option for evalu-
ting global coronary microcirculation conditions in these
atients.
The aim of this prospective, multicenter, observational
tudy was to compare the prognostic value of CFR in the
AD in diabetic and nondiabetic patients with known or
uspected CAD and negative dipyridamole stress echocar-
iography for wall motion criteria.
ethods
atients. The initial population comprised 1,544 patients
rospectively enrolled at 5 Italian cardiology institutions
Lucca, Mestre, Cesena, Pisa, Napoli) from August 2003 to
une 2006. All patients underwent stress echocardiography
ith CFR assessment of LAD by transthoracic Doppler
ltrasound. Of the 1,544 patients initially selected for the
tudy, 85 (6%) were excluded for inadequate echocardio-
raphic image quality precluding satisfactory imaging of
AD flow, 31 (2%) for side effects requiring premature test
nterruption, and 298 (19%) for test positivity by wall
otion criteria. Thus, 1,130 patients (629 men, age 63 11
ears) with a negative stress echocardiography by wall
otion criteria formed the study group. Of them, 207 were
iabetic patients (18). Indication to stress echocardiography
as suspected CAD in 712 (63%) and risk stratification of
nown CAD (i.e., history of myocardial infarction, coronary
evascularization, and/or angiographic evidence of 50%
iameter coronary stenosis) in 418 (37%) subjects. Exclu-
ion criteria were significant valvular or congenital heart
isease, prognostically relevant noncardiac diseases (cancer,
nd-stage renal disease, or severe obstructive pulmonary
isease), and inadequate acoustic window precluding satis-
actory imaging of left ventricle (for 2-dimensional echo-
ardiography) or of LAD flow Doppler (for CFR assess-
ent). Arterial hypertension (19) and hypercholesterolemia
20) were defined according to standard definitions. Ac-
ording to individual needs and physicians’ choices, 666
59%) patients were evaluated after antianginal drugs had
een discontinued, and 464 (41%) patients were evaluated
uring antianginal treatment (Table 1). Of the 207 diabetic
atients, 159 were on oral antidiabetics, 46 on insulin
herapy, and 2 on both. The study was approved by the
nstitutional review board. All patients gave their written
nformed consent when they underwent stress echocardiog-
aphy. When patients signed the written informed consent
hey also authorized physicians to use their clinical data.
tress echocardiography data were collected and analyzed by
tress echocardiographers not involved in patient care.
tress echocardiography. Transthoracic stress echocardio-
raphic studies were performed with commercially available
ltrasound machines (Sonos 5500-7500, Philips Ultra-
ound, Andover, Massachusetts; Sequoia C256, Acuson
r
Wiemens, Mountain View, Cali-
ornia; and Vivid System 7, GE/
ingmed, Milwaukee, Wiscon-
in) equipped with multifrequency
hased-array sector scan probe
S3–S8 or V3–V7) and with sec-
nd harmonic technology. Two-
imensional echocardiography and
2-lead electrocardiographic mon-
toring were performed in combi-
ation with high-dose dipyrida-
ole (up to 0.84 mg over 6 min)
21). Echocardiographic images
ere semiquantitatively assessed
sing a 17-segment, 4-point scale
odel of the left ventricle (22). A wall motion score index was
erived by dividing the sum of individual segment scores by the
umber of interpretable segments. Ischemia was defined as
tress-induced new and/or worsening of pre-existing wall
otion abnormality. Rest wall motion abnormality was aki-
etic or dyskinetic myocardium with no thickening during
tress. A test was normal in case of no rest and stress wall
otion abnormality.
Coronary flow reserve was assessed during the standard
tress echocardiography examination by an intermittent
maging of both wall motion and LAD flow (9). Coronary
ow in the mid-distal portion of LAD was searched for in
haracteristics of the Study Population
Table 1 Characteristics of the Study Population
Age (yrs) 63 11
Men 629 (56%)
Clinical history
Prior myocardial infarction 310 (27%)
Prior coronary revascularization 321 (28%)
Prior CABG 61 (5%)
Prior PCI 260 (23%)
Known CAD 418 (37%)
Left bundle branch block 67 (6%)
Family history of CAD 231 (20%)
Diabetes 207 (18%)
Arterial hypertension 723 (64%)
Hypercholesterolemia 627 (55%)
Smoking habit 323 (29%)
Anti-ischemic therapy at the time of test
Beta-blockers 335 (30%)
Calcium antagonists 224 (20%)
Nitrates 149 (13%)
At least 1 medication 464 (41%)
Echocardiogram
Resting WMSI 1.14 0.27
Resting LVEF (%) 56 8
Resting WMA 341 (30%)
CFR 2.41 0.58
CFR 2 309 (27%)
ata presented are mean  standard deviation or number (%) of patients.
CABG  coronary artery bypass grafting; CAD  coronary artery disease; CFR  coronary flow
Abbreviations
and Acronyms
CAD  coronary artery
disease
CFR  coronary flow
reserve
LAD  left anterior
descending coronary artery
NSTEMI  non–ST-segment
elevation myocardial
infarction
STEMI  ST-segment
elevation myocardial
infarctioneserve; LVEF  left ventricular ejection fraction; PCI 
MA  wall motion abnormality; WMSI  wall motion scpercutaneous coronary intervention;
ore index.
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Coronary Flow Reserve in Diabetic Patients October 2, 2007:1354–61he low parasternal long-axis section under the guidance of
olor Doppler flow mapping (23). In 402 (36%) patients
ith no visualization of color-coded blood flow from the
AD at the baseline condition, the procedure was at-
empted a second time during contrast enhancement with
onovue (Bracco-Byk-Gulden, Konstanz, Germany) in bo-
us (0.5 ml intravenously) (Fig. 1).
All studies were digitally stored to simplify off-line
eviewing and measurements. Coronary flow parameters
ere analyzed off-line by use of the built-in calculation
ackage of the ultrasound unit. Flow velocities were mea-
ured at least twice for each study: at baseline and at peak
tress (before aminophylline injection). At each time point,
optimal profiles of peak diastolic Doppler flow velocities
ere measured, and the results were averaged. Coronary
ow reserve was defined as the ratio between hyperemic
eak and basal peak diastolic coronary flow velocities. A
alue of CFR 2 was considered abnormal. All observers
ere trained by the same senior investigator (F.R.), who
ranted consistency in data acquisition, storage, and inter-
retation, also through intensive joint reading sessions. All
nvestigators of contributing centers passed quality control
riteria for regional wall motion and Doppler interpretation
efore entering the study as previously described (24). The
reviously assessed intra- and interobserver variability for
easurements of Doppler recordings and regional wall
otion analysis assessment were 10% (9).
ollow-up data. Outcome was determined from patients’
nterview at the outpatient clinic, hospital chart reviews, and
elephone interviews with the patient, his/her close relative,
r referring physician. The clinical events recorded during
he follow-up were death, nonfatal acute coronary syn-
romes (ST-segment elevation myocardial infarction
Figure 1 Protocol of Dipyridamole Stress Echocardiography
The stress protocol was based on the intermittent evaluation of wall motion and c
anterior descending artery during dipyridamole (DIP) infusion. BP  blood pressureSTEMI] or non–ST-segment elevation myocardial infarc-
ion [NSTEMI]), and clinically driven coronary revascular-
zation (surgery or angioplasty). In order to avoid misclas-
ification of the cause of death (25), overall mortality was
onsidered. ST-segment elevation myocardial infarction was
efined by typical symptoms, ST-segment elevation on
lectrocardiogram, and cardiac enzyme changes. Non–ST-
egment elevation was an acute coronary syndrome causing
ypical chest pain, cardiac enzyme elevation, and/or electro-
ardiographic modifications consistent with acute ischemia
26) requiring hospitalization. Follow-up data were ana-
yzed for the prediction of death, STEMI, or NSTEMI.
tatistical analysis. Continuous variables are expressed as
ean  standard deviation. Differences in continuous
ariables were assessed with the unpaired t test; the chi-
quare test was used for categorical variables. Survival rates
ere estimated with Kaplan-Meier curves and compared by
he log-rank test. Patients undergoing coronary revascular-
zation were censored at the time of the procedure. Only the
rst event was taken into account. Annual event rates were
btained from Kaplan-Meier estimates to take censoring of
he data into account. The association of selected vari-
bles with outcome was assessed with the Cox propor-
ional hazard model using univariate and stepwise mul-
ivariate procedures. A significance of 0.05 was required
or a variable to be included into the multivariate model,
hereas 0.1 was the cutoff value for exclusion. Hazard
atios with the corresponding 95% confidence intervals
ere estimated. Statistical significance was set at a value
f p  0.05. Statistical Package for the Social Sciences
SPSS release 13.0, SPSS Inc., Chicago, Illinois) was
sed for analysis.
y flow reserve (CFR) in the left
pulsed wave; 2D echo  2-dimensional echocardiography.oronar
; PW 
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tress echocardiography. No major complications occurred
uring the test. Of 1,130 patients, 341 (30%) exhibited resting
all motion abnormality (165 on the LAD territory), and 789
70%) no wall motion abnormality at rest. Coronary flow
eserve was abnormal in 309 (27%) cases. No difference in
FR was observed between the 165 patients with resting wall
otion abnormality on the LAD territory and those with
ormal regional function (2.34  0.66 vs. 2.42  0.57, p 
.13). Patients with abnormal CFR were older (65 11 years
s. 63  11 years, p  0.003), had higher incidence of
ypercholesterolemia (64% vs. 52%, p  0.0004), and arterial
ypertension (69% vs. 62%, p  0.03), higher resting wall
otion score index (1.19 0.34 vs. 1.12 0.25, p 0.0001),
nd underwent stress echocardiography more frequently under
nti-ischemic therapy (50% vs. 37%, p 0.0001) than patients
ith normal CFR. No difference in resting flow diastolic
elocity was found between hypertensives and normotensives
30  10 cm/s vs. 30  8 cm/s, p  0.63), patients with and
ithout hypercholesterolemia (30 10 cm/s vs. 29 8 cm/s,
 0.34), and patients with and without resting wall motion
bnormality (30  10 cm/s vs. 29  9 cm/s, p  0.29).
atients with abnormal CFR had slightly higher resting flow
elocities than patients with normal CFR (33 11 cm/s vs. 29
8 cm/s, p  0.03) and markedly lower peak flow velocities
59  19 cm/s vs. 74  21 cm/s, p  0.002).
In the 207 diabetic patients, the mean value of glycosy-
ated hemoglobin (HbA1c) was 6.9  1.5%. Glycosylated
emoglobin was similar in diabetic patients with normal
nd abnormal CFR (7.0  1.5% vs. 6.7  1.5%, p  0.82).
linical and echocardiographic characteristics of the study
opulation are reported in Table 1.
ollow-up events. During a median follow-up of 16
onths (first quartile 8, third quartile 26 months), there
Univariate and Multivariate Prognostic Predicto
Table 2 Univariate and Multivariate Prognos
Univariat
HR (95% CI)
Age (yrs) 1.02 (1.00–1.04)
Gender (male) 0.81 (0.54–1.20)
Prior infarction 1.31 (0.86–1.98)
Prior revascularization 0.67 (0.42–1.08)
Known CAD 1.18 (0.89–1.76)
Left bundle branch block 1.18 (0.52–2.70)
Family history of CAD 1.14 (0.68–1.90)
Diabetes 1.85 (1.19–2.89)
Hypertension 1.49 (0.96–2.31)
Hypercholesterolemia 1.51 (0.99–2.31)
Smoking habit 0.96 (0.61–1.51)
Anti-ischemic therapy 2.39 (1.59–3.60)
CFR 2 5.43 (3.60–8.19)
Left ventricular ejection fraction 0.99 (0.97–1.01)
Resting WMSI 1.63 (0.89–2.99)
Resting WMA 1.64 (1.10–2.45)CI  confidence interval; HR  hazard ratio; other abbreviations as in Tableere 98 hard events (8 deaths, 24 STEMI, and 66
STEMI). Twenty-seven events occurred in diabetic and
1 in nondiabetic patients (13% vs. 7.7%, p  0.01).
atients on beta-blocking agents at time of testing had a
igher incidence of events when compared with those off
eta-blocking therapy (14% vs. 6.4%, p  0.001). Addi-
ionally, 101 patients underwent revascularization (18 sur-
ery and 83 angioplasty) after a median of 193 days from the
ndex stress echocardiography: 29 diabetic and 72 nondia-
etic patients (14% vs. 7.8%, p  0.005). There were 59
evascularizations in patients with abnormal CFR and 42 in
hose with normal CFR (19% vs. 5%, p  0.0001). The
-year event rate associated with abnormal and normal CFR
as not different (pNS) between patients with or without
esting wall motion abnormalities (38% vs. 36% and 11% vs.
%, respectively).
utcome prediction. Univariate and multivariate prog-
ostic indicators are reported in Table 2. Abnormal CFR
as the strongest independent predictor of future events
p  0.0001), followed by anti-ischemic therapy at the time
f testing (p  0.002), age (p  0.02), and rest wall motion
bnormality pattern (p  0.05) (Table 2).
Abnormal CFR was associated with markedly higher
vent rates (p  0.0001) than normal CFR in both the
iabetic and nondiabetic populations (Fig. 2).
The annual event rate in the entire population of
iabetic and nondiabetic patients was 9.3% and 5.1%,
espectively. When test negativity was obtained off ther-
py, the presence of a normal CFR identified a group of
iabetic and nondiabetic patients with similar low annual
vent rate (2.2% vs. 2.0%, p  0.80). Conversely, when
FR was abnormal, it was associated with higher risk in
iabetic patients, independent of the presence of con-
omitant therapy.
redictors
ysis Multivariate Analysis
p Value HR (95% CI) p Value
0.009 1.02 (1.00–1.04) 0.02
0.30
0.21
0.10
0.42
0.69
0.63
0.006
0.08
0.06
0.86
0.0001 1.96 (1.29–2.98) 0.002
0.0001 4.95 (3.26–7.50) 0.0001
0.18
0.11
0.02 1.50 (1.00–2.25) 0.05rs
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tress echocardiography is a recognized technique for the
rognostic assessment of diabetic patients (3–7). In one
tudy, the result of test similarly identified groups with
ifferent risk profile in diabetic and nondiabetic subjects (7).
evertheless, a negative test was less prognostically benign
n diabetic patients than in age-matched nondiabetic pa-
ients (7), consistent with the increased cardiovascular risk
ssociated with diabetes (1,2,7,27–29). The search for more
ccurate and effective risk stratification strategies is critical
n diabetic patients in order to optimize therapeutic inter-
entions. In the current study, we found abnormal CFR in
he LAD to be a strong, independent and additive prog-
ostic indicator in a large cohort of patients with known or
uspected CAD and negative dipyridamole stress echocar-
iography by standard wall motion criteria. Clinically driven
evascularizations were also more frequent in patients with
educed than in those with preserved CFR. In keeping with
revious findings (30), concomitant anti-ischemic therapy
as also a strong predictor of unfavorable outcome. Inter-
stingly, the interaction between CFR and anti-ischemic
herapy provided an effective prognostic stratification. In the
ontext of a relatively low-risk clinical setting, as that of
atients with negative stress echocardiography result (7) off
herapy, a preserved CFR identified diabetic and nondia-
etic patients with better survival and comparable yearly
vent rate. On the basis of present results, a negative test off
herapy with normal CFR confers a benign prognosis
ndependent of diabetes. Conversely, abnormal CFR was
ssociated with markedly increased annual risk in diabetic
atients that was only marginally modulated by concomitant
herapy. It is in this subset of patients that a more aggressive
pproach is warranted with a tight metabolic control,
aximal anti-ischemic therapy, and a more frequent
ollow-up by noninvasive stress testing. A watchful surveil-
ance is strongly recommended in those with a test negativ-
ty under medical therapy and abnormal CFR. Consistent
ith previous reports (31), no relation between HbA1c and
Figure 2 Kaplan-Meier Survival Curves
Event rate for diabetic and nondiabetic patients with coronary flow reserve (CFR) FR was found in our study population. Explanations for teduced CFR in the absence of stress-induced wall motion
bnormalities include mild-to-moderate epicardial coronary
rtery stenosis (32), severe epicardial coronary artery stenosis
n presence of anti-ischemic therapy (33–36), and severe
icrovascular coronary disease in presence of patent epicar-
ial coronary arteries (37,38). Noteworthy, an impairment
f CFR has been documented in both type 1 and 2 diabetes
ellitus without coronary artery stenosis by using different
echniques (39–41). All these pathophysiological condi-
ions may determine impairment of CFR and may adversely
ffect prognosis (15,27,41–45) (Fig. 3). Contrast ultrasound
tudies have demonstrated that myocardial perfusion abnor-
alities of clear prognostic impact can occur even when wall
otion response is normal (46). Also, studies have shown
hat when there is existing wall motion abnormality at rest,
he lack of biphasic response or worsening of wall motion
as a very poor ability to exclude CAD (47). The unchanged
all motion response can still coexist with residual CFR,
ossibly mostly in the subepicardial layer, which is not
eflected in changes in wall motion during stress but may
xert prognostically beneficial antiremodelling and antiar-
hythmic effects (48). In fact, the regional wall motion
esponse during stress is tightly linked to subendocardial—
ather than transmural or subepicardial—perfusion (49).
In recent years, vasodilator stress echocardiography with
ombined assessment of CFR in the LAD has entered the
chocardiography lab as a feasible technique (8), providing
dditional diagnostic value over conventional wall motion
nalysis (9–14). However, the relative prognostic effect of
FR remains largely unexplored. In a previous study,
bnormal CFR was independently associated with the
ccurrence of spontaneous events or late revascularizations
n unselected patients with unchanged wall motion contrac-
ility during stress (15). In addition, abnormal CFR was a
trong predictor of death or worsening of clinical status in
onischemic dilated cardiomyopathy (50). Finally, CFR was
redictive of ventricular remodeling—a recognized indicator
f unfavorable outcome (51)—after acute myocardial infarc-
2.2 or ion treated by primary angioplasty (52).
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October 2, 2007:1354–61 Coronary Flow Reserve in Diabetic PatientsIn this study, there was no central reading. Stress echo-
ardiography and CFR measurement were interpreted in
he peripheral centers and entered directly in the data bank.
his system allowed substantial sparing of human and
echnologic resources, but it was also the logical prerequisite
or a large scale study, designed to represent the realistic
erformance of the test rather than the results of a single
ab—or even a single person—working in a highly dedi-
ated echocardiography laboratory. Because the assessment
f the echocardiograms was qualitative and subjective,
ariability in reading the echocardiograms might have mod-
lated the results of individual centers (45). However, all
ur readers in individual centers had a long-lasting experi-
nce in echocardiography, passed the quality control in
tress echocardiography reading as previously described
53), and had extensive experience on performance and
nterpretation of CFR also through joint reading sessions.
ne limitation of the Doppler technique is related to the
eed of a maximal vasodilation in order to compare rest and
eak diastolic velocities, whereas the rest velocities may
xert a prognostically significant meaning only when mea-
ured in a quantitative way as it happens with positron
mission tomography (54). The study was not designed to
ddress the effect of antidiabetic therapy; therefore enrolling
enters evaluated each single patient according to referring
hysicians’ prescriptions. We cannot also exclude that dur-
ng the follow-up period antidiabetic therapy may have been
hanged in relation to glycemic and HbA1c levels improving
Figure 3 Synthetic View of Different Coronary Anatomic and Pr
A synthetic view of the different coronary anatomic (first row) and prognostic coro
during stress (framed). In normal conditions (left), there is normal coronary anato
(third row), with 3-fold increase in peak diastolic flow velocity during stress (dotte
can be found in presence of prognostically meaningful microvascular disease (sec
With more advanced epicardial coronary artery stenosis (far right column), the red
unfavorable prognostic impact (   good prognosis;   possibly unfavorable pr
nary artery disease. Redrawn and modified from Picano et al. (32).he overall metabolic state.eprint requests and correspondence: Dr. Lauro Cortigiani,
ivisione di Cardiologia Ospedale “Campo di Marte,” 55032
ucca, Italy. E-mail: lacortig@tin.it.
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